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Background: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 (Oxford-
AstraZeneca) COVID-19 vaccines have demonstrated high efficacy against infection in phase 
3 clinical trials and are now being used in national vaccination programmes in the UK and 
several other countries. There is an urgent need to study the ‘real-world’ effects of these 
vaccines. The aim of our study was to estimate the effectiveness of the first dose of these 
COVID-19 vaccines in preventing hospital admissions.
Methods: We conducted a prospective cohort study using the Early Pandemic Evaluation and 
Enhanced Surveillance of COVID-19 (EAVE II) database comprising of linked vaccination, 
primary care, Real-Time Polymerase Chain Reaction (RT-PCR) testing, hospitalisation and 
mortality records for 5.4 million people in Scotland (covering ~99% of population). A time-
dependent Cox model and Poisson regression models were fitted to estimate effectiveness 
against COVID-19 related hospitalisation (defined as 1- Adjusted Hazard Ratio) following the 
first dose of vaccine.
Findings: The first dose of the BNT162b2 vaccine was associated with a vaccine effect of 85% 
(95% confidence interval [CI] 76 to 91) for COVID-19 related hospitalisation at 28-34 days 
post-vaccination. Vaccine effect at the same time interval for the ChAdOx1 vaccine was 94% 
(95% CI 73 to 99). Results of combined vaccine effect for prevention of COVID-19 related 
hospitalisation were comparable when restricting the analysis to those aged ≥80 years (81%; 
95% CI 65 to 90 at 28-34 days post-vaccination).
Interpretation: A single dose of the BNT162b2 mRNA and ChAdOx1 vaccines resulted in 
substantial reductions in the risk of COVID-19 related hospitalisation in Scotland. 
Funding: UK Research and Innovation (Medical Research Council); Research and Innovation 
Industrial Strategy Challenge Fund; Health Data Research UK. 















Evidence before this study 
We searched PubMed and medRxiv for observational studies using the terms “COVID-19 
vaccine effect”. We found one preprint that reported a 51% relative risk reduction against 
SARS-CoV-2 infection 13-24 days after the first dose of the BNT162b2 mRNA (Pfizer-
BioNTech) vaccine. This study used data from a state-mandated health provider in Israel 
covering 503,875 individuals. We also found a correspondence article that reported adjusted 
rate reductions for SARS-CoV-2 infections of 30% and 75%, respectively for the periods 1–14 
and 15–28 days after the first dose of the BNT162b2 vaccine in a cohort of 9,109 healthcare 
workers in Israel’s largest hospital.
Added value of this study 
UK policy for use of vaccines against COVID-19 involves an offer of a first dose followed by 
a second dose 12 weeks later. To our knowledge, this is the first study of COVID-19 vaccine 
effect against hospitalisation for an entire nation after a single dose of vaccine. We found that 
a single dose of BNT162b2 COVID-19 vaccine was associated with a vaccine effect (VE) of 
85% (95% CI 76 to 91) for COVID-19 hospitalisation 28-34 days post-vaccination. A single 
dose of ChAdOx1 vaccine was associated with a vaccine effect 94% (95% CI 73 to 99) at 28-
34 days post-vaccination. VEs increased over time with a peak at 28-34 days post-vaccination 
for both vaccines. Comparable VEs were seen in those aged ≥80 years for prevention of 
COVID-19 hospitalisation with a high combined VE of 81% (95% CI 65 to 90) at 28-34 days 
post-vaccination. 
Implications of all the available evidence
We provide compelling evidence that the two COVID-19 vaccines currently being used in the 
UK vaccination programme substantially reduce the risk of COVID-19 related hospital 
admissions in the population who are at highest risk for severe COVID-19 outcomes. 














In December 2019, there was an outbreak of a novel Severe Acute Respiratory Coronavirus 
(SARS-CoV-2) in Wuhan, China, which was later declared as a Coronavirus disease (COVID-
19) pandemic by the World Health Organization (WHO).[1] As of 14 February 2021, more 
than 108 million cases and 2.3 million deaths have been reported in over 223 countries and 
territories.[1] The UK has among the highest morbidity and mortality rates worldwide. 
Scotland has reported more than 21,000 hospitalisations and 6,700 deaths due to COVID-19.[2] 
There has been an unprecedented investment in vaccine technology, evaluation, and production 
in response to the pandemic. Authorisation of the first COVID-19 vaccines occurred soon after 
publication of the initial phase 3 safety and efficacy studies.[3] The UK was one of the first 
countries to license these vaccines.[2] As of 18 February 2021, first dose vaccine coverage of 
over 22% has been reported in Scotland with over 1.3 million vaccines administered across the 
Scottish population, and delivery targeting specified priority groups of those most at risk of 
harm (including the elderly and healthcare workers).[2,4] 
Clinical trials of all three currently UK authorised vaccines (i.e., Pfizer-BioNTech, Oxford-
AstraZeneca and Moderna) have reported high vaccine efficacy. For the Pfizer-BioNTech 
vaccine (BNT162b2 mRNA COVID-19 Vaccine), 95% efficacy was reported against 
laboratory confirmed COVID-19.[5] The Oxford-AstraZeneca vaccine was found to have 70% 
efficacy against symptomatic COVID-19 amongst seronegative participants.[6] The Moderna 
vaccine (mRNA-1273) was reported to have 95% efficacy against confirmed COVID-19, but 
it will not be administered in the UK until Spring 2021 at the earliest, and is therefore not 
included in this analysis.[7] 
Large post-licensure epidemiological studies are needed to complement the findings of pre-
licensure trials and assess the effectiveness of these vaccines at the population level in ‘real-
world’ settings.[8] The COVID-19 vaccination policy of the UK is at odds with the 
manufacturer guidance on timing between the first and second dose. Reflecting the need to 
gather evidence on this policy, we sought to assess the effectiveness of the first doses of the 
Pfizer-BioNTech and Oxford-AstraZeneca vaccines against COVID-19 related hospital 
admissions amongst adults in Scotland. 














Study design and population 
We constructed an open, real-time prospective observational cohort with national level 
coverage in Scotland using a unique dataset consisting of linked vaccination, primary care, 
laboratory testing, hospitalisation, and mortality data (see Figure 1 in Supplementary Material). 
Data were available for 5.4 million people in Scotland.[9] Primary care data derived from 940 
general practices across Scotland were linked to the laboratory data from the Electronic 
Communication of Surveillance in Scotland (ECOSS),[9] the hospital admission data available 
from the Scottish Morbidity Record (SMR) 01 database and Rapid Preliminary Inpatient Data 
(RAPID),[10] and mortality data available from the death registry within National Records of 
Scotland (NRS).[9] Vaccination data were available from general practices and the Turas 
Vaccination Management Tool (TVMT),[11] which is a web-based tool to capture vaccinations 
in the community and create real-time vaccination records. Laboratory data from ECOSS 
included all Real-Time Polymerase Chain Reaction (RT-PCR) test results from both NHS 
laboratories (Pillar 1) and Lighthouse Government laboratories (Pillar 2).[12] 
Exposure definition
We studied the first doses of the BNT162b2 mRNA COVID-19 (also known as the Pfizer-
BioNTech) vaccine [5] and ChAdOx1 nCoV-19 (AZD1222; also known as the Oxford-
AstraZeneca) vaccine.[6] An individual was defined as exposed if they received a single dose 
of vaccine between 8th December 2020 and 15th February 2021, with maximum follow-up 
time censored at 15th February 2021 - the latest event date. Vaccinated groups were stratified 
by time intervals including 7-13, 14-20, 21-27, 28-34, 35-41 and >42 days post-vaccination, 
and by the type of vaccine received. Vaccinations information was extracted from the GP 
records and included individuals vaccinated in community hubs and in general practice.
Definition of outcomes
We assessed VE against hospital admissions with COVID-19 as the main cause of admission, 
or hospital admission within 28 days of a positive RT-PCR test for SARS-CoV-2 infection 
from 8 December 2020 to 13 February 2021. See Table 1 in Supplementary Material for ICD-
10 codes used for COVID-19 illness. 














Patient characteristics and confounders
At the baseline of our cohort (8th December 2020), a number of population characteristics that 
could potentially confound the association between COVID-19 vaccination and the outcomes 
of interest were determined. These included age, sex, socio-economic status (SES) measured 
by quintiles of the Scottish Index of Multiple Deprivation (SIMD) (1 refers to most deprived 
and 5 refers to least deprived),[9] residential settlement measured by the urban/rural 6 fold 
classification (1 refers to large urban areas and 6 refers to small remote rural areas),[9] and the 
number and types of comorbidities commonly associated with COVID-19 illness.[9]
Statistical analysis 
The primary analyses included VE estimates for vaccination status overall and for each vaccine 
type. The secondary analysis included VE estimates for vaccine status overall stratified by age 
groups (18-64, 65-79 and >80 years old). 
Baseline characteristics in the vaccinated and unvaccinated groups were described using 
proportions and risk ratios (RRs). We assessed the effect of one dose of either vaccine against 
hospital admissions related to laboratory confirmed SARS-CoV-2 infection, or clinical 
diagnosis of COVID-19 on admission. Poisson regression adjusting for an offset representing 
the time at risk and time-dependent Cox models (taking into account the time at risk) were used 
to derive the RRs and hazard ratios (HR) and 95% confidence intervals (CIs) for the prevention 
of COVID-19 hospitalisation, where the HR was derived from the coefficient of vaccine status 
in the model. 
Cox models included spline terms for age and number of RT-PCR tests prior to vaccination (a 
marker for healthcare workers, social care workers and care home residents who had repeated 
tests). Additional adjustments were made for sex, SES and underlying medical conditions at-
risk of COVID-19 illness with vaccination groups representing a time-dependent covariate. 
Calendar time intervals by week were included as stratification variables. Poisson regression 
was used for the full adjustment and propensity weighting. This used age groups in 5 year 
intervals and adjustment for the following clinical conditions, all of which are associated with 
an increased risk of hospitalisation: Type 1 and type 2 diabetes, high and low blood pressure, 
chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), dementia, 
stroke, learning disorders, fractures, neurological conditions, chronic cardiac failure, asthma, 














epilepsy, blood cancer, liver cirrhosis, venous thromboembolism (VTE), peripheral vascular 
disease, atrial fibrillation, pulmonary hypertension, Parkinson’s disease, rare pulmonary 
disorders, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  
The analysis was repeated using Poisson regression, with age groups and test groups. The 
Poisson regression results are presented. The statistical model results are derived from a subset 
of the data by selecting those without the event for each event and performing a weighted 
regression. The weights reflected two aspects. First, the sample weights were used to correct 
for the size of the registered GP population being bigger than the population in Scotland. These 
weights were derived by matching the age and sex numbers in the GP data to the Scottish 
population data. Second, the weights reflected the sampling frequency of controls.
The models were fit to a dataset with all events and a random sample, without replacement, of 
100 individuals per event with sample weights calculated to represent the sampling fraction. A 
combined weight was used in the statistical modelling. A propensity model for vaccination was 
developed using a logistic regression model including terms for age group, SES, sex, number 
of previous PCR tests and number of clinical risk groups. A final adjustment included using 
inverse propensity weighting.
Individuals who had previously tested positive (by RT-PCR) for SARS-CoV-2 infection prior 
to 8th December 2020 were excluded from this analysis. All statistical tests were two-tailed 
with a 5% significance level. 
The statistical software R (Version 3.6.1) was used to carry out all statistical analysis.[13]
Ethics and permissions 
Approvals were obtained from the National Research Ethics Service Committee, Southeast 
Scotland 02 (reference number: 12/SS/0201) and Public Benefit and Privacy Panel for Health 
and Social Care (reference number: 1920-0279). 
Reporting
We produced a detailed analysis protocol prior to undertaking the analysis. We followed the 
Strengthening the Reporting of Observational studies in Epidemiology (STROBE) [14] and 













Reporting of studies Conducted using Observational Routinely-collected Data (RECORD) [15] 
checklists to guide transparent reporting of this cohort study (see Tables 2 and 3 in 
Supplementary Material). We will make our analysis code available on GitHub at the time of 
publication. 
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or the writing of this report. 
Results
Vaccine uptake by baseline characteristics 
Between 8 December 2020 to 15 February 2021, 1,137,775 (35%) patients were vaccinated in 
our study. Rapid uptake of BNT162b2 mRNA and ChAdOx1 vaccines was observed over the 
study period (Figure 1 and Table 1), with the largest increase amongst the first priority target 
group aged ≥ 80 years. For the BNT162b2 mRNA vaccine, high uptake rate was found in 
patients <65 years old  while for the ChAdOx1 vaccine, higher vaccine uptake was found in 
patients >80 years old (Figure 2). The subgroups with highest vaccine uptake for both vaccine 
combined were females (30.6%), the second least deprived quintile of SIMD (27.5%), those 
living in remote rural areas (33.2%), those with five or more comorbidities (72.2%), ex-
smokers (42.3%) and those with very raised blood pressure (39.1%) (Table 1). 
Vaccine effect against hospital admissions
During all time periods after vaccination, a statistically significant adjusted VE was found 
against COVID-19 related hospital admissions among those who received the first dose of 
either BNT162b2 or ChAdOx1 vaccines (Table 2). 
We found that VEs increased over time until a peak at day 28-34 days post-vaccination for 
both vaccines. The highest VE against COVID-19 hospitalisation amongst those receiving the 
first dose of the vaccine BNT162b2 was 85%, (95% CI 76 to 91) and for ChAdOx1 it was 94% 
(95% CI 73 to 99) (Table 2). 
Similar findings were observed in a pooled analysis for both vaccines of VE against COVID-
19 hospitalisation stratified by age group (Table 3). High VEs were found amongst all age 














groups. VE estimates for 18-64, 65-79 and ≥80 year olds were highest at 28-34 days after the 
first dose of vaccine (85%, 95% CI 68 to 93; 79%, 95% CI 17 to 95; 81%, 95% CI 65 to 90, 
respectively). 
Discussion
This national prospective cohort study comprising almost the entire Scottish population 
demonstrated that a single dose of either the BNT162b2 mRNA or ChAdOx1 vaccines was 
associated with substantial protection against COVID-19 hospitalisation. Peak VEs of 85% for 
the BNT162b2 vaccine and 94% for the ChAdOx1 vaccine were found against COVID-19 
related hospitalisations. In the oldest age group (≥80 years), based on a pooled analysis for both 
vaccines, we observed peak VE of 81% against COVID-19 related hospitalisations. VE tended 
to increase over time after the first dose for this age group, with the optimal time being >28 
days. 
Two studies from Israel have reported on the vaccine effect of BNT162b2 mRNA. Using data 
on over 500,000 individuals, an effect of 51% was demonstrated for the first dose against 
SARS-CoV-2 infection 13-24 days after immunisation.[16] A cohort study of 9,109 healthcare 
workers in Israel’s largest hospital reported adjusted rate reductions for SARS-CoV-2 
infections of 30% and 75% for the periods 1–14 and 15–28 days after the first dose of the 
BNT162b2 vaccine.[17] There have also been recent news reports of a study using a dataset 
consisting of 1.2 million people from the Clalit Institute in Israel finding 94% VE against 
symptomatic infection for those having received two doses of the Pfizer-BioNTech 
vaccine.[18] Complementary to these three studies, we have found high VE against COVID-
19 hospitalisation for the BNT162b2 mRNA and ChAdOx1 vaccines after a single dose.
This is, to our knowledge, the first national population level study assessing the effect of 
currently licensed COVID-19 vaccines on a serious COVID-19 outcome. Our study has several 
strengths. We developed a national linked dataset and have created a platform which allowed 
rapid access to and analysis of data on vaccination status and medical condition status from 
routinely collected electronic health records (EHR) data and national databases.[9,19] This 
study is therefore less susceptible to recall or misclassification bias than studies of sub-samples 
of the population. The inclusion of large population samples increased the study power, 
facilitating estimation of VE in multiple age groups and time intervals after the first dose of the 













vaccination. We are likely to have excellent generalisability across the UK and potentially other 
countries with national programmes using these same vaccines.  
 
Our study also had several limitations. First, we estimated vaccine effects against COVID-19 
related hospital admission. However, there are other outcomes of interest, including GP and 
accident & emergency (A&E) department consultations, ICU admission, death, rate of 
secondary SARS-CoV-2 infection within households as well as maternal and neonatal 
outcomes. We did not estimate VE against these outcomes. Second, although our VE estimates 
were adjusted for potential confounders, unmeasured confounders could still have influenced 
our estimates.  In addition, the effect of confounding likely differed between age groups. 
Individuals aged ≥80 years have been universally offered vaccination, whereas only those 
designated as clinically extremely vulnerable or at high occupation risk have been targeted for 
the receipt of a vaccine amongst the 18-65 year age group.[4] Also the ChAdOx1 vaccine has 
predominantly been used in the elderly and was only available from 4th January 2021, giving 
less time for follow-up. Finally, although we have large population samples, there was an 
insufficient number of people who had received the second dose of the vaccines to reliably 
study VE after receiving a full course of vaccination. However, the VE of a single dose is of 
policy interest given the ongoing debate over whether to defer a second dose to allow more 
rapid population coverage. 
 
Monitoring the effect of currently licensed vaccines in the general population needs to be 
continued in Scotland and the other UK nations, especially in high-risk subgroups such as those 
in care homes where more data will be needed to produce reliable VE estimates. Similarly, 
further monitoring to assess the effect of receiving two doses, rather than just one, is needed. 
Robust observational epidemiological studies should be carried out to measure the coverage of 
these newly introduced vaccines in relation to demographic and other population characteristics 
and to detect adverse events. These post-marketing observational studies will add value to the 
pre-licensure clinical trials as they can assess ‘real-life’ effects of the COVID-19 vaccines and 
the impact of the vaccination programme at a population level.  We plan in due course to report 
on the effectiveness of the second dose and the effects on mortality.
In summary, we provide compelling national evidence that the first doses of the BNT162b2 
mRNA and ChAdOx1 vaccines protect against COVID-19 hospitalisations in adults.  
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Figure 1: COVID-19 vaccine uptake by age over time
    
Figure 2: Vaccine uptake by age and vaccine type (AZ: Oxford-AstraZeneca. PB: Pfizer-
BioNTech).
























Female 697,506 (61.3) 1,583,408 (48.4) 30.6 1
Male 440,269 (38.7) 1,688,428 (51.6) 20.7 0.68
Age group (years)
18-64 395,439 (34.8) 2,989,015 (91.4) 11.7 1
65-79 535,607 (47.1) 223,349 (6.8) 70.6 6.04
>80 206,729 (18.2) 59,473 (1.8) 77.7 6.65
Socio-economic Status
1 – Most deprived 191,510 (16.8) 674,542 (20.6) 22.1 1
2 220,609 (19.4) 645,735 (19.7) 25.5 1.15
3 238,986 (21.0) 634,121 (19.4) 27.4 1.24
4 240,467 (21.1) 635,293 (19.4) 27.5 1.24
5 – Least deprived 240,370 (21.1) 646,240 (19.8) 27.1 1.23
Unknown 5,833 (0.5) 35,905 (1.1) 14.0 0.63
Urban/rural score
1 – Large urban area 353,190 (31.0) 1,237,574 (37.8) 22.2 1
2 415,063 (36.5) 1,137,322 (34.8) 26.7 1.2
3 115,015 (10.1) 288,174 (8.8) 28.5 1.28
4 66,692 (5.9) 144,696 (4.4) 31.6 1.42
5 109,712 (9.6) 282,899 (8.6) 27.9 1.26
6 – Remote rural area 72,270 (6.4) 145,699 (4.5) 33.2 1.49
Unknown 5,833 (0.5) 35,910 (1.1) 14.0 0.63
Number of comorbidities
0 479,656 (42.2) 2,167,916 (66.3) 18.1 1
1 320,130 (28.1) 782,067 (23.9) 29.0 1.6
2 174,284 (15.3) 223,653 (6.8) 43.8 2.42
3 88,995 (7.8) 64,847 (2.0) 57.8 3.19














4 43,659 (3.8) 21,393 (0.7) 67.1 3.7
>5 31,051 (2.7) 11,960 (0.4) 72.2 3.98
Asthma 147,942 (13.0) 411328 (12.6) 26.5 1.03
Chronic Kidney 
condition (Level 3)
121,584 (10.7) 39,951 (1.2) 75.3 3.15
Liver cirrhosis 9,595 (0.8) 13,744 (0.4) 41.1 1.60
Chronic neurological 
condition
6,395 (0.6) 11,719 (0.4) 35.3 1.37
Heart Failure 32,059 (2.8) 16,044 (0.5) 66.6 2.63
Diabetes (type 1) 5,229 (0.5) 16,193 (0.5) 24.4 0.95
Diabetes (type 2) 130,674 (11.5) 127,870 (3.9) 50.5 2.08
Dementia 30,742 (2.7) 7,069 (0.2) 81.3 3.21
Coronary Heart Disease 128,040 (11.3) 74,070 (2.3) 63.4 2.64
Smoking Status
Ex-smoker 240,969 (21.2) 328,066 (10.0) 42.3 1.61
Smoker 259,727 (22.8) 648,129 (19.8) 28.6 1.09
Non-smoker 439,324 (38.6) 1,238,432 (37.9) 26.2 1
Unknown 133,650 (11.7) 697,620 (21.3) 16.1 0.51
Blood pressure level (systolic/diastolic)
Very high 
(>160/100mmHg)




151,030 (13.3) 247,750 (7.6) 37.9 1.21
Normal
(110-140/65-90 mmHg)
735,389 (64.6) 1,616,986 (49.4) 31.3 1
Low
(<110/65 mmHg)
11,142 (1.0) 42,537 (1.3) 20.8 0.66
Unknown 133,650 (11.7) 697,620 (21.3) 16.1 0.51














Table 2. COVID-19 hospitalisation and days post-vaccination for both BNT162b2 and 




















Unvaccinated 787518 7472 1 1 1 NA
Vaccine dose 1 (7-
13 days)
13487 212 0.73 (0.64 to 0.84) 0.74 (0.64 to 
0.86)
0.53 (0.47 to 0.61) 47% (39 to 53)
Vaccine dose 1 
(14-20 days)
9191 120 0.61 (0.5 to 0.73) 0.63 (0.52 to 
0.76)
0.4 (0.34 to 0.48) 60% (52 to 66)
Vaccine dose 1 
(21-27 days)
6343 52 0.43 (0.33 to 0.56) 0.44 (0.33 to 
0.58)
0.3 (0.23 to 0.38) 70% (62 to 77)
Vaccine dose 1 
(28-34 days)
3867 20 0.34 (0.22 to 0.52) 0.31 (0.2 to 
0.48)
0.16 (0.1 to 0.26) 84% (74 to 90)
Vaccine dose 1 
(35-41 days)
2326 17 0.6 (0.38 to 0.97) 0.46 (0.28 to 
0.76)
0.39 (0.26 to 0.58) 61% (42 to 74)
Vaccine dose 1 
(42+ days)
3843 21 0.52 (0.34 to 0.81) 0.51 (0.33 to 
0.79)
0.42 (0.3 to 0.61) 58% (39 to 70)
BNT162b2 or Pfizer-BioNTech
Unvaccinated 708129 6690 1 1 1 NA
Vaccine dose 1 (7-
13 days)
7766 104 0.71 (0.58 to 0.86) 0.56 (0.46 to 
0.68)
0.62 (0.53 to 0.72) 38% (28 to 47)
Vaccine dose 1 
(14-20 days)
5758 60 0.61 (0.47 to 0.78) 0.42 (0.32 to 
0.55)
0.4 (0.32 to 0.5) 60% (50 to 68)
Vaccine dose 1 
(21-27 days)
4688 34 0.43 (0.31 to 0.6) 0.29 (0.21 to 
0.41)
0.28 (0.21 to 0.38) 72% (62 to 79)
Vaccine dose 1 
(28-34 days)
3346 18 0.33 (0.21 to 0.53) 0.22 (0.14 to 
0.35)
0.15 (0.09 to 0.24) 85% (76 to 91)
Vaccine dose 1 
(35-41 days)
2275 17 0.46 (0.28 to 0.73) 0.29 (0.18 to 
0.48)
0.32 (0.21 to 0.47) 68% (53 to 79)
Vaccine dose 1 
(42+ days)
3842 21 0.38 (0.25 to 0.58) 0.32 (0.21 to 
0.51)
0.36 (0.25 to 0.51) 64% (49 to 75)
ChAdOx1nCoV-19 or Oxford-AstraZeneca
Unvaccinated 700859 7090 1 1 1 NA
Vaccine dose 1 (7-
13 days)
5721 108 0.49 (0.41 to 0.6) 0.51 (0.42 to 
0.62)
0.3 (0.24 to 0.37) 70% (63 to 76)
Vaccine dose 1 
(14-20 days)
3433 60 0.4 (0.31 to 0.52) 0.46 (0.35 to 
0.6)
0.26 (0.19 to 0.34) 74% (66 to 81)














Vaccine dose 1 
(21-27 days)
1655 18 0.24 (0.15 to 0.38) 0.29 (0.18 to 
0.47)
0.16 (0.1 to 0.28) 84% (72 to 90)
Vaccine dose 1 
(28-34 days)
521 2 0.08 (0.02 to 0.33) 0.1 (0.03 to 
0.41)
0.06 (0.01 to 0.27) 94% (73 to 99)
Vaccine dose 1 
(35-41 days)
51 0 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) NA
Vaccine dose 1 
(42+ days)
1 0 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) NA
NA=not applicable
*Adjusted for: age
**Adjusted for: time (in weeks), age, sex, SIMD, number of RT-PCR tests prior to vaccination and number of underlying 
medical conditions.
***Adjusted for: time (in weeks), age, sex, SIMD, number of RT-PCR tests prior to vaccination and number of underlying 
medical conditions and inverse propensity of being vaccinated
Omitting individuals who had previously tested positive














Table 3.  COVID-19 hospitalisation by age group and days post-vaccination (BNT162b2 and 
ChAdOx1nCoV-19


















Unvaccinated 609892 3202 1 1 1 NA
Vaccine dose 
1 (7-13 days)
5467 46 1.4 (1.04 to 
1.87)









4805 21 0.74 (0.48 to 
1.14)
0.7 (0.45 to 1.08) 0.67
(0.51 to 0.88)




3933 9 0.39 (0.2 to 
0.74)








2824 3 0.18 (0.06 to 
0.56)








1894 6 0.53 (0.24 to 
1.19)








3291 8 0.41 (0.21 to 
0.83)




51% (23 to 69)
Unvaccinated 137190 2409 1 1 1 NA
Vaccine dose 
1 (7-13 days)
4230 51 0.59 (0.44 to 
0.77)








1199 20 0.74 (0.48 to 
1.16)








504 7 0.65 (0.31 to 
1.36)

















145 4 1.5 (0.56 to 
4.01)




56% (-46 to 
86)
















213 7 1.82 (0.87 to 
3.82)




8% (-105 to 
59)
Unvaccinated 40436 1861 1 1 1 NA
Vaccine dose 
1 (7-13 days)
3789 115 0.67 (0.56 to 
0.81)








3188 79 0.55 (0.44 to 
0.69)








1906 36 0.41 (0.29 to 
0.57)
0.5 (0.35 to 0.72) 0.25
(0.17 to 0.37)




795 14 0.37 (0.22 to 
0.62)
0.39 (0.23 to 
0.68)




288 7 0.49 (0.23 to 
1.03)








339 6 0.36 (0.16 to 
0.79)
0.37 (0.16 to 
0.85)
0.2 (0.08 to 0.51) 80% (49 to 92)
NA=not applicable
*Adjusted for: age
**Adjusted for: time (in weeks), age, sex, SIMD, number of RT-PCR tests prior to vaccination and number of underlying 
medical conditions.
***Adjusted for: time (in weeks), age, sex, SIMD, number of RT-PCR tests prior to vaccination and number of underlying 
medical conditions and inverse propensity of being vaccinated
Omitting individuals who had previously tested positive
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